Press release
Biosimilar Monoclonal Antibodies Market Survey Detailed Analysis and Forecast 2024-2031
The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02 Billion in 2022 and is predicted to reach 26.14 Billion by the year 2031 at a 20.5 % CAGR during the forecast period for 2023-2031.
Get A Free Report Brochure: https://www.insightaceanalytic.com/request-sample/1218
The production of monoclonal antibodies (mAb) entails using identical immune cell clones from a single original progenitor cell. They are referred to as biosimilar monoclonal antibodies because all monoclonal antibodies generated by a parent cell are similar, as they are all clones of the same parent cell. Biosimilars are biotherapeutic products. They are comparable to state-of-the-art reference pharmaceutical products in terms of safety, efficacy, and quality. The mAb biosimilars are complex biological macromolecules that have undergone numerous post-translational modifications. These biosimilars are effective in the treatment of a variety of chronic, inflammatory, and autoimmune disorders. The global market for biosimilar monoclonal antibodies is experiencing growth due to the increasing production of advanced monoclonal antibodies, the ageing population, and the high prevalence of chronic diseases such as cancer, kidney failure, rheumatoid arthritis, psoriasis, and diabetes.
More opportunities for market expansion are anticipated in the years ahead as more of mAbs' patents expire. It is anticipated that the demand for mAbs will increase rapidly during the forecast period because of the increased patent expirations of the most prominent antibodies. Nevertheless, the market's growth is anticipated to be impeded by the complexity of biological pharmaceutical production, the lack of clinical trial experience, the strict government regulations for product approvals, and the need for more awareness and understanding among manufacturers regarding biosimilar regulation and approval. North America is anticipated to be the primary contributor to the Biosimilar Monoclonal Antibodies market in the forecast years.
The region's robust growth can be attributed to well-established healthcare infrastructure, increased product approvals, and a favourable reimbursement scenario. In addition, the Asia-Pacific regional market is anticipated to experience substantial growth during the estimated period due to the increasing burden of chronic diseases, the demand for affordable therapies, and government funding for healthcare facility enhancements.
Order this Premium Report: https://www.insightaceanalytic.com/buy-report/1218
Major market players operating in the Biosimilar Monoclonal Antibodies market include
BioXpress Therapeutics (Switzerland), Intas Pharmaceuticals Limited (Gujarat), Genor BioPharma Co. Ltd (China), BIOCAD (Russia), Dr. Reddys Laboratories Ltd (Hyderabad), 3SBio (China), Reliance Life Sciences (India), Hisun Pharma (China), Celgen Biopharma (China), Torrent Pharmaceuticals (Ahmedabad), Cadila Healthcare (Cadila Healthcare), Mylan Inc. (US) and others.
Recent collaborations and agreements in the market:
• In July 2021, Abzena (UK), BioXpress Therapeutics (Switzerland) and a global partner research organization for biologics and bioconjugates have partnered to assist with developing third-party biosimilars. This partnership led to the development of an integrated solution by two prominent service providers in biosimilar development and GMP manufacturing.
• In February 2021, Ogivri, a trastuzumab biosimilar, was introduced by Mylan (US). Trastuzumab, previously marketed as Herceptin by Genentech, is a monoclonal antibody used to treat human epidermal growth factor receptor 2 (HER2)- positive breast cancer.
Get Specific Chapter/Information From The Report: https://www.insightaceanalytic.com/customisation/1218
Market Segments
Global Biosimilar Monoclonal Antibodies Market, by Indication, 2022-2030 (Value US$ Mn)
• Oncology
• Inflammatory & Autoimmune Disorders
• Chronic Diseases
• Blood Disorders
• Other Indication
Global Biosimilar Monoclonal Antibodies Market, by Product, 2022-2030 (Value US$ Mn)
• Infliximab
• Trastuzumab
• Rituximab
• Adalimumab
• Bevacizumab
• Cetuximab
• Ranibizumab
• Denosumab
• Eculizumab
• Other Pipeline Products
Global Biosimilar Monoclonal Antibodies Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Biosimilar Monoclonal Antibodies Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa
Why should buy this report:
> To obtain a thorough examination of the outlook for the global Biosimilar Monoclonal Antibodies market
> To obtain an industry overview and prospective trends of the Biosimilar Monoclonal Antibodies market
> To evaluate the drivers and obstacles of the Biosimilar Monoclonal Antibodies market
> To obtain information regarding the Biosimilar Monoclonal Antibodies market value (US$ Mn) forecast through 2030
> Significant investments, mergers, and acquisitions in the Biosimilar Monoclonal Antibodies market industry
Details insights on this market: https://www.insightaceanalytic.com/report/global-biosimilar-monoclonal-antibodies-market/1218
Corporate Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
Sales Office (U.S.) :
344 Grove St Unit #967 Jersey City, NJ 07302
email: info@insightaceanalytic.com
North America:
+1 551 226 6109
Asia:
+91 79 72967118
Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/InsightaceA
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilar Monoclonal Antibodies Market Survey Detailed Analysis and Forecast 2024-2031 here
News-ID: 3526751 • Views: …
More Releases from Insightace analytic
Digital Pathology Market Report- Expansive Coverage on the Profit Sources
InsightAce Analytic announces the release of a market assessment report on the "Global Digital Pathology Market Size, Share & Trends Analysis Report By Product (Artificial Intelligence, Scanner, Software, Storage), Type (Human, Veterinary), Application (Teleconsultation, Training, Disease Diagnosis, Drug Discovery), End User (Pharma, Academia, Hospitals)- Market Outlook And Industry Analysis 2031"
The global digital pathology market is estimated to reach over USD 2731.95 million by 2031, exhibiting a CAGR of 12.91%…
Digital Health Market Future Trends and Scope Analysis Report
Digital Health Market Size, Share & Trends Analysis Report By Technology (Tele-healthcare, mHealth, Healthcare Analytics, Digital Health Systems), By Component (Software, Hardware, Services), By Region, And Segment Forecasts, 2024-2031
"Digital Health Market" in terms of revenue was estimated to be worth $248.58 billion in 2023 and is poised to reach $1,004.03 billion by 2031, growing at a CAGR of 19.56% from 2023 to 2031, according to a new report by…
Digital Diabetes Management Market Report on the Untapped Growth Opportunities i …
InsightAce Analytic announces the release of a market assessment report on the "Global Digital Diabetes Management Market - (By Devices (Smart Glucose Meters, Continuous Glucose Monitoring Systems, And Smart Insulin Pens, Smart Insulin Pumps/ Closed-Loop Pumps & Smart Insulin Patches), Application (Diabetes & Blood Glucose Tracking Apps, Obesity & Diet Management Apps), Data Management Software & Platforms And Services), By Device Type (Handheld And Wearable Devices), By End-User(Self/Home Healthcare, Hospitals…
Data Center Liquid Cooling Market Exclusive Trends Analysis with Forecast to 203 …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Data Center Liquid Cooling Market Size, Share & Trends Analysis Report By End-User Industry (Financial Services And Insurance (BFSI), Banking, IT And Telecom, Government And Public Sector, Manufacturing, Healthcare, Retail), Data Center (Hyperscale, Colocation, Enterprise) And Solution (Indirect & Direct Cooling)- Market Outlook And Industry Analysis 2031"
The Global Data Center Liquid Cooling Market is estimated…
More Releases for Biosimilar
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
Biosimilar Insulin Market Access
Boston, MA
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer…
Biosimilar Insulin Market Access
ReportsWorldwide has announced the addition of a new report title Biosimilar Insulin Market Access to its growing collection of premium market research reports.
Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure.
The launch of the biosimilar insulin Basaglar is a threat to the insulin-based product market, which includes long-time reference product Lantus as well as newer entrants…
Biosimilar Insulin Market Biosimilar Insulin Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Prologue to Insulin Biosimilars
1.1 Outline Towards Insulin
1.2 Trail of Insulin Evolution and Development
Rationale Design of Insulin Molecule
2.1 Structure of Insulin Polypeptide
2.2 Biosynthesis of Insulin
2.3 Secretion of Insulin
Mechanism of Insulin in Diabetics
3.1 Glucose Metabolism of Insulin
3.2 Impact of Insulin Dysregulation in Diabetes 1
3.3 Impact…
Global Biosimilar Insulin Market To Witness Exponential Growth With 15 Commercia …
“Global Biosimilar Insulin Market Opportunity and Clinical Insight Outlook 2022” report gives comprehensive insight on clinical and non-clinical issues involved with growth of global biosimilar insulin market. This report analyzes various aspects like rationale design of insulin molecule, mechanism of insulin in diabetes, engineering of synthetic insulin, global aspects of biosimilar insulins along with market overview, biosimilar insulin clinical pipeline insight and future trends for the development of…
India Biosimilar Market Analysis
As the number of patent expiries of biologic drugs is increasing, Indian companies are developing biosimilar manufacturing capabilities. Firms are developing their capabilities by either forming partnerships with R&D-intensive firms or outsourcing to upcoming Indian contract research organizations (CROs). Domestic manufacturers have a cost advantage (lower facility and development costs) than peers in developed countries. Moreover, Indian firms seem keen on repeating their successes achieved in developing and commercializing biosimilars.…
